Search
Displaying all 2 results
Lusutrombopag
go.drugbank.com/drugs/DB13125
ApprovedInvestigational
Lusutrombopag is an orally bioavailable thrombopoietin receptor (TPOR) agonist developed by Shionogi & Company (Osaka, Japan). TPOR is a regulatory target site for endogenous thrombopoietin, which acts as a primary cytokine to promote megakaryocyte proliferation and differentiation, and affect other hematopoieti...
Chronic immune thrombocytopenia
go.drugbank.com/conditions/DBCOND0023252